文献速递脊柱关节炎

司库奇尤单抗与TNF抑制剂在脊柱关节炎中的一年治疗结局:五项北欧生物制剂注册研究超万例疗程分析

One-Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2022-03-08

基于五项北欧临床风湿病注册研究2015-2018年数据,纳入10,853个治疗疗程(司库奇尤单抗842例,TNFi 10,011例,其中阿达木单抗1,977例),比较司库奇尤单抗与TNFi(以阿达木单抗为主要对照)在脊柱关节炎患者中的治疗有效性。结果显示司库奇尤单抗主要用于生物制剂经治患者,作为一线或二线治疗时一年保留率与阿达木单抗相当,但三线及以上治疗时保留率和6个月应答率均劣于阿达木单抗。

要点

  • 司库奇尤单抗主要在一线1%、二线6%、三线及以上22%的患者中使用,属生物制剂经治人群为主。
  • 一线或二线治疗时司库奇尤单抗一年保留率与阿达木单抗相当,三线及以上时较差(56% vs 70%,HRadj 1.43)。
  • 6个月应答率各治疗线司库奇尤单抗均劣于阿达木单抗,仅三线及以上有统计学意义。

核心结论

  • 司库奇尤单抗在脊柱关节炎中主要用于生物制剂经治患者,随既往生物制剂暴露增加,阿达木单抗优于司库奇尤单抗。
  • 一线或二线治疗时司库奇尤单抗一年保留率与阿达木单抗相当,但6个月应答率数值上均较低。

研究设计与样本

  • 观察性前瞻性队列研究,数据来自五项北欧临床风湿病注册研究,纳入2015-2018年开始司库奇尤单抗或TNFi的脊柱关节炎患者。
  • 共纳入10,853个治疗疗程,其中司库奇尤单抗842例、TNFi 10,011例(阿达木单抗1,977例)。
  • 合并症与关节外表现取自国家注册库(94%患者有数据),并纳入多变量分析。

主要发现

  • 司库奇尤单抗在一线、二线、三线及以上治疗中的使用比例分别为1%、6%、22%。
  • 三线及以上治疗时司库奇尤单抗一年保留率56%(95%CI 51-61%)低于阿达木单抗70%(95%CI 64-75%),HRadj 1.43(95%CI 1.12-1.81)。
  • 三线及以上治疗6个月应答率:ASDAS<2.1的OR 0.56(95%CI 0.35-0.90),BASDAI<40 mm的OR 0.62(95%CI 0.41-0.95)。
  • 五种TNFi之间治疗结局存在差异。

关键数值与推荐

  • 一年治疗保留率采用粗生存曲线及校正后停药风险比(HRadj)评估。
  • 6个月应答率定义为ASDAS<2.1和BASDAI<40 mm,采用粗分析及LUNDEX校正的校正逻辑回归(OR)评估。
  • 分析按生物制剂治疗线(一线、二线、三线及以上)分层。

临床怎么用

  • 脊柱关节炎患者一线或二线生物制剂治疗时,司库奇尤单抗可作为与阿达木单抗相当的选项。
  • 对已经历多种生物制剂失败的患者,选择阿达木单抗可能优于司库奇尤单抗。
  • 处方司库奇尤单抗时应考虑患者既往生物制剂暴露线数对疗效的影响。

局限性

  • 为观察性研究,存在混杂因素,尽管已进行多变量校正。
  • 司库奇尤单抗组样本量(842例)远小于TNFi组(10,011例),且主要集中于经治患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe baseline characteristics and to compare treatment effectiveness of secukinumab versus tumor necrosis factor inhibitors (TNFi) in patients with spondyloarthritis (SpA) using adalimumab as the main comparator. METHODS: This was an observational, prospective cohort study. Patients with SpA (clinical ankylosing spondylitis, nonradiographic axial SpA, or undifferentiated SpA) starting secukinumab or a TNFi during 2015-2018 were identified from 5 Nordic clinical rheumatology registries. Data on comorbidities and extraarticular manifestations (psoriasis, uveitis, and inflammatory bowel disease) were captured from national registries (data available in 94% of patients) and included in multivariable analyses. We assessed 1-year treatment retention (crude survival curves, adjusted hazard ratios [HRadj ] for treatment discontinuation) and 6-month response rates (Ankylosing Spondylitis Disease Activity Score [ASDAS] score <2.1, Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] <40 mm, crude/LUNDEX-adjusted, adjusted logistic regression analyses with odds ratios [ORs]) stratified by line of biologic treatment (first, second, and third plus). RESULTS: In total, 10,853 treatment courses (842 secukinumab and 10,011 TNFi, of which 1,977 were adalimumab) were included. The proportions of patients treated with secukinumab during the first, second, and third-plus lines of treatment were 1%, 6%, and 22%, respectively). Extraarticular manifestations varied across treatments, while other baseline characteristics were largely similar. Secukinumab had a 1-year retention comparable to adalimumab as a first or second line of treatment but poorer as a third-plus line of therapy (secukinumab 56% [95% confidence interval (95% CI) 51-61%] versus adalimumab 70% [95% CI 64-75%]; HRadj 1.43 [95% CI 1.12-1.81]). Across treatment lines, secukinumab had poorer estimates for 6-month response rates than adalimumab, statistically significantly only for the third-plus line (adjusted analyses: ASDAS score <2.1 OR 0.56 [95% CI 0.35-0.90]; BASDAI <40 mm OR 0.62 [95% CI 0.41-0.95]). Treatment outcomes varied across the 5 TNFi. CONCLUSION: Secukinumab was mainly used in biologics-experienced patients with SpA. Secukinumab and adalimumab performed similarly in patients who had failed a first biologic, although with increasing prior biologic exposure, adalimumab was superior.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Glintborg B, Lindström U, Giuseppe DD, et al. One-Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses. Arthritis Care Res (Hoboken). 2022. PMID: 33253491. doi:10.1002/acr.24523

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。